dementia-2019-keynote

4 / 4

allied
academies
September 16-17, 2019 | Paris, France
Dementia and Alzheimer's Disease
13th World Congress on
Page 11
Journal of Clinical Psychiatry and Cognitive Psychology | Volume: 03
Zdenka Kristofikova,
Ricny J
National Institute of Mental Health, Czech Republic
New biomarkers of Alzheimer’s disease in Cerebrospinal fluid
Causes of Alzheimer´s disease is not known and ideal
biomarkers (100% sensitivity, 100% specificity)
of this type of dementia have not been revealed yet.
Current biomarkers (levels of amyloid beta 1-42, tau and
phospho-tau) in cerebrospinal fluid are often estimated
in a combination in order to increase their sensitivity
and specificity. Recently, we evaluated new diagnostic
biomarkers in cerebrospinal fluid (the ratio of Thioflavin-
T-based fluorescence to intrinsic amyloid fluorescence
(sensitivity 61.1%, specificity 70.8% compared to
nondemented controls), levels of mitochondrial 17beta-
hydroxysteroid dehydrogenase type 10 – amyloid beta
1-42 (sensitivity 41.1%, specificity 83.3% compared to
nondemented controls), levels of mitochondrial 17beta-
hydroxysteroid dehydrogenase type 10 – mitochondrial
cyclophilin D (sensitivity 92.9%, specificity 91.7% compared
to nondemented controls but only 26.2% compared to
Frontotemporal lobal degeneration). Significant changes
of all our prospective biomarkers were observed already
in early stages of disease (the group of mild-cognitive
impairment related to Alzheimer´s diseases), however,
specificities failed when compared to other types of
dementia. Nevertheless, we can recommend the ratio
of Thioflavin-T based fluorescence to intrinsic amyloid
fluorescence (reflecting oligomers to aggregates rate)
in cerebrospinal fluid as the relatively cheap and easily
accessible supportive diagnostic biomarker of Alzheimer´s
disease. Moreover, the above-mentioned complexes
of two mitochondrial proteins (17beta-hydroxysteroid
dehydrogease type 10 and cyclophilin D) in cerebrospinal
fluid seem to be the highly sensitive biomarker of
neurodegeneration. Supported by AZV project of Ministry
of Health of the Czech Republic (16-27611A).
Speaker Biography
Neurochemist Zdenka Kristofikova studied at Czech Technical Univerzity
in Prague (Ing., Department of Nuclear Chemistry) and at Univerzity
of Defence, Faculty of Military Health Sciences in Hradec Kralove
(PhD, Department of Toxicology), both in the Czech Republic. At the
present time, she works as a researcher and a head of working group
in Department of Experimental Neurobiology of National Institute of
Mental Health, Czech Republic. She has over 100 publications that
have been cited over 600 times, and her publication H-index is 15.
She is interested in cerebrospinal fluid or serum/plasma biomarkers
and various animal models (genetic as well as pharmacological) of
Alzheimer´s disease for a long time.
e: